Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Cervical cancer is one of the major health problems for chinese women. Besides surgery and
radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many
studies. However, not all patients respond well to neoadjuvant chemotherapy. This is an
open-label, single-arm, multi-center clinical trial to evaluate whether PD-1 in combination
with neoadjuvant chemotherapy will achieve better objective response rate.
Phase:
Phase 2
Details
Lead Sponsor:
Huazhong University of Science and Technology
Collaborators:
Army Medical University Chongqing University Cancer Hospital First Affiliated Hospital of Chongqing Medical University Harbin Medical University Obstetrics & Gynecology Hospital of Fudan University Peking University People's Hospital Qilu Hospital of Shandong University Tianjin Medical University General Hospital Women's Hospital School Of Medicine Zhejiang University